FIT at 74% sensitivity produces more false negatives than ColoSTAT (81% sensitivity) - in other words ColoSTAT detects more actual CRC than FIT, however the flipside is that FIT at 96 specificity produces less false positives than ColoSTAT (91%specificity).
If you don't believe me, I suggest you read the major Metanalysis papers re performance of FIT and compare to the ColoSTAT study 7 data.
One final observation I will make is that Study 7 with only 989 samples (they probably had 5 cases of CRC of which ColoSTAT missed 1 of the 5) would be more or less be considered a "pilot study" for the US FDA.
A prospective study of 15K to 20K samples will be required for FDA approval for which RHY will need to raise US$40M+ or more to fund - that's a big raise compared to the current US$4.5M Rights Issue!.
RHY Price at posting:
12.5¢ Sentiment: None Disclosure: Not Held
